Overview of Nanotechnology Drug Delivery MarketThe global Nanotechnology Drug Delivery Market is valued at USD 97.98 Billion ...

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

The evolution of nanotechnology is transforming the landscape of drug delivery, offering new avenues to address challenges in medicine. Antibody-drug ...

Indian pharma powers ahead with research on NDDS for painless, precision medicine delivery: Nandita Vijayasimha, Bengaluru Thursday, July 10, 2025, 08:00 Hrs [IST] Indian pharma i ...

Fujifilm Pharma’s liposomal formulation of gemcitabine FF-10832 receives US FDA’s orphan drug designation to treat biliary tract cancer: Cambridge, Massachusetts Wednesday, Ju ...

The Global Liposomal Supplements Market is valued at approximately USD 323.4 million in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Fujifilm’s FF-10832, an investigational liposomal formulation of gemcitabine, for the treatment of biliary tract ...

Two examples of FDA-approved intracameral implants are Durysta (Allergan) and iDoseTR (Glaukos), both of which provide ...

In the quest for optimal health and longevity, many individuals are turning to innovative dietary supplements designed to ...

Liposomes are essential vehicles for membrane protein reconstitution and drug delivery, making them vital tools in both in vivo and in vitro studies. However, the lack of robust techniques for the ...